Recordati Ireland Limited

Dompe' Farmaceutici S.p.a.

Recordati Industria Chimica E Farmaceutica S.p.a.

Recordati Industria Chimica E Farmacentica S.p.a.

Patrizia Angelico

Marcello Allegretti

Amedeo Leonardi

Carlo Riva

Davide Graziani

Elena Poggesi

Carlo De Toma

Maria Candida Cesta

Andrea Aramini

Gianluca Bianchini

Laura Brandolini

Luciano Guarneri

Sergio Menegon

Matteo Longhi

Elisa Callegari

Fabio Frigerio

Elena Poggessi

The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB), also including IC/PBS and/or OAB induced by anticancer therapy. Methods of treatment and/or prevention, combinations and kits comprising said IL-8 inhibitors are also covered therein.

IL-8 inihibitors for use in the treatment of some urological disorders

This invention relates to compounds of formula I; and their use as antagonists of P2Xand P2Xreceptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of pain and chronic pain and tolerance to analgesic, respiratory disorders and dysfunctions, and treatment of overactive bladder, bladder pain syndrome, dysuria and in general in genitourinary diseases, cardiovascular disorders and more in general for the potential treatment of visceral organ diseases and disorders characterized by the involvement of P2Xand P2Xreceptors.

P2Xreceptor antagonists

This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction. 

Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors

This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.

Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors

Growing community of inventors

Sesto S. Giovanni, Italy

Patrizia Angelico